Clinical Trials and Studies

The University of Washington’s Memory and Brain Wellness Center serves as a site for international clinical trials and studies of potential treatments, prevention strategies, and new diagnostic approaches for Alzheimer’s Disease and related neurodegenerative conditions, in the earliest stages. We represent the clinical trial activities at the UW Alzheimer’s Disease Research Center (ADRC) and showcase relevant clinical trials running in other UW Medicine departments. This page provides information about enrolling clinical trials and how you can learn more or participate. New trials appear over time, and these may involve other groups of patients. We think of study participants as our partners in the effort to find a prevention for neurological conditions that lead to dementia.

With new tools to detect the brain’s level of amyloid plaques, researchers have found that the pathology starts to accumulate in the brain 10 to 25 years before tangles of tau protein and cognitive impairment occur, much like cholesterol plaques slowly build up in arteries decades before causing heart attacks or strokes. The conclusion: catching the disease early is key. Researchers now agree that treatment may be more effective if given to the patients in the earliest stages of Alzheimer disease.

Clinical studies provide a controlled and monitored environment where volunteer research participants can safely take experimental medication. Most of the trials at our center are placebo-controlled, double-blind studies, meaning that there is a chance that participants will be on the experimental medication or on a placebo (a substance that looks the same but contains no medication).

For expanded information about participating in Alzheimer disease research studies at the UW, please visit Participating in Research and Brain Donation.

Guide to Clinical Trials and Studies at the UW

You may be eligible if you have:

Biogen Emerge

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

The EMERGE Study is a global study assessing the efficacy and safety of monthy doses of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease or prevent dementia. There is an important medical and scientific need to research therapies that could delay memory loss and the progression of disability in Alzheimer’s disease because there are currently no approved treatments that slow the course of the condition.

 

You may be eligible to participate in EMERGE if you

  • are 50-85 years old
  • are experiencing symptoms that may be related to early Alzheimer’s disease, such as problems with memory or thinking clearly.

 

Key UW researcher: Suman Jayadev, MD

Study Coordinator: Teah Hoopes, thoopes@uw.edu or 1-844-861-9373 (toll free)


CONNECT

A Multi-Center, Double-Blind, Placebo-Controlled Phase 11a Study to Evaluate an Investigational Medicine to Treat Mild Alzheimer's Disease. The CONNECT Study will test whether an experimental drug, AZD0530 (saracatinib) will slow the progression in mild-stage Alzheimer's disease.

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

Neuroimaging and Function Study

The purpose of this UW Department of Rehabilitation Medicine study is to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems.  The study involves two visits (one year apart) to the University of Washington Health Sciences Center.  At the first visit a magnetic resonance imaging (MRI) is taken of the brain.  Walking, balance and memory tests are completed.  At the second visit only walking, balance and memory tests are completed. Taxi transportation is provided if needed.  Participants receive $50 for the first visit and $30 for the second visit.

 

Key Researcher: Ellen McGough, PhD, UW Assistant Professor, Department of Rehabilitation Medicine

Study Coordinator: Monica Smersh

Study Contact Number: 206-598-6139 or 206-616-5550

For More Information

SNIFF

The Study of Nasal Insulin to Fight Forgetfulness (SNIFF)

This Phase II/III clinical trial will examine whether a type of insulin, when administered intranasally (as a nasal spray), improves memory in adults with a mild cognitive impairment or Alzheimer’s disease. The study will also provide evidence about how intranasal insulin works in the body.

Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

Biogen Emerge

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

The EMERGE Study is a global study assessing the efficacy and safety of monthy doses of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease or prevent dementia. There is an important medical and scientific need to research therapies that could delay memory loss and the progression of disability in Alzheimer’s disease because there are currently no approved treatments that slow the course of the condition.

 

You may be eligible to participate in EMERGE if you

  • are 50-85 years old
  • are experiencing symptoms that may be related to early Alzheimer’s disease, such as problems with memory or thinking clearly.

 

Key UW researcher: Suman Jayadev, MD

Study Coordinator: Teah Hoopes, thoopes@uw.edu or 1-844-861-9373 (toll free)


HABIT® Healthy Action to Benefit Independence & Thinking

*Study In Progress - Currently Not Enrolling

HABIT® Healthy Action to Benefit Independence & Thinking - A 10-Day Brain and Body Wellness Program for people living with mild cognitive impairment and a support partner

The Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD) Study of HABIT

HABIT is a 10-day program offered to individuals with cognitive impairment. A support partner is required to complete the program with the participant. The program builds on existing strengths and recognizes that procedural memory, otherwise known as 'habit,' can be exercised to promote the highest level of function and independence.

In the CEPIPODD study, participants will be randomly assigned to engage daily in 4 of these 5 components of HABIT:

  • Individual memory compensation training
  • Group supportive therapy
  • Yoga
  • Brain fitness
  • Wellness education

These sessions are delivered by a caring, multidisciplinary HABIT team including psychologists, education specialists, cognitive interventionalists, and exercise specialists.

Key UW Researcher: Vaishali Phatak

Study Contact: Marigrace Becker at mbecker1@uw.edu | 206.744.2017


Neuroimaging and Function Study

The purpose of this UW Department of Rehabilitation Medicine study is to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems.  The study involves two visits (one year apart) to the University of Washington Health Sciences Center.  At the first visit a magnetic resonance imaging (MRI) is taken of the brain.  Walking, balance and memory tests are completed.  At the second visit only walking, balance and memory tests are completed. Taxi transportation is provided if needed.  Participants receive $50 for the first visit and $30 for the second visit.

 

Key Researcher: Ellen McGough, PhD, UW Assistant Professor, Department of Rehabilitation Medicine

Study Coordinator: Monica Smersh

Study Contact Number: 206-598-6139 or 206-616-5550

For More Information

SNIFF

The Study of Nasal Insulin to Fight Forgetfulness (SNIFF)

This Phase II/III clinical trial will examine whether a type of insulin, when administered intranasally (as a nasal spray), improves memory in adults with a mild cognitive impairment or Alzheimer’s disease. The study will also provide evidence about how intranasal insulin works in the body.

Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

A4 Study

Anti-amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) prevention clinical trial

The A4 Study is a landmark clinical trial that is testing a new drug that may help slow memory loss associated with Alzheimer’s disease. [Read about A4 in Spanish.]

 

You may be eligible to join the A4 study if you:

Are 65 to 85 years old

Have normal thinking and memory abilities

Have an A4 study partner – someone who has at least weekly contact with you who can answer questions once a year

Are willing and able to receive IV infusions of the investigational treatment or placebo for 36 months (36 monthly infusions); all A4 participants must be willing and able to participate in all required procedures for the duration of the A4 study.

Are willing to have your health monitored throughout the study using assessments such as:

Memory and thinking tests

ECGs (a look at your heart)

PET scan (a way to look for the plaques thought to be associated with AD)

MRI scans (a way to take a picture of your brain)

Blood and urine tests

 

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

Brain Aging in Vietnam War Veterans (DOD-ADNI)

Official Title: Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)

Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat-related problems and may be associated with a greater risk of Alzheimer's disease. This study will examine the possible connections between TBI and PTSD, and the signs and symptoms of Alzheimer's in Vietnam War veterans as they age.

 

Key ADRC Researcher Elaine Peskind, MD

Study Contact Jacqueline Hayes | 415-221-4810 | Jacqueline.Hayes@va.gov


GOLD: Brain Games to Overcome Late Life Depression

The University of Washington Department of Psychiatry and Behavioral Sciences is conducting a research study to see whether new treatments are effective for depressed, older adults.

We are looking for people aged 60 and older who are struggling with mood, depression or low energy. Every day we learn more and more about what causes depression. We know that not everyone is depressed for the same reasons and that there is no “one-size-fits-all” treatment for low mood, concentration and energy. Can a video game that helps older brains work like younger brains be useful in treating depression? Answering this question will help us develop “brain games” that can treat certain types of depression. Participants must be able to participate in MRI scans.

 

Participant Eligibility

Age 60- 80
Experiencing symptoms of depression
Able to participate in MRI scans

 

Key UW researcher Patricia Areán

Contact Mary Ann Barnard (206) 616-2129

For More Information

Meal and Memory Study

APOE genotype and diet influences on Alzheimer's biomarkers

We are learning more and more about the risks for Alzheimer's disease every year, and that includes learning what foods are best at promoting brain health.  It might be more complicated than 'this food is good or bad.'  Dr. Angela Hanson, a geriatric physician at the University of Washington, is conducting a study that examines how a risk gene for Alzheimer's disease might affect people's memory and metabolic responses to different meals.  Her preliminary work showed that people who carry the gene APOE4 (E4) responded differently to different Alzheimer's treatments and diets, compared to people who did not carry this gene.  Dr. Hanson plans to study this further with the "Meal and Memory Study” in adults age 55 and older who do not have dementia. 

 

Eligibility: Participants may be men or women, ages 55 and older. People who have known dementia, or known diabetes, are not eligible.

 

Key researcher:  Angela Hanson, MD

Study Contact: Angela Hanson at 206-897-5393 or hansonaj@uw.edu

For More Information

The 18F-AV-1451 Autopsy Study

Avid Radiopharmaceuticals is evaluating a new imaging tracer, 18F-AV-1451, to see if it can identify the build-up of tau protein associated with Alzheimer’s disease and other conditions that lead to dementia. Tau accumulation in the brain can gradually cause problems with thinking and remembering. Until now, these tau tangles could only be seen by using a microscope to look at the brain of a patient after they died. This study aims to determine if, using 18F-AV-1451, it may be possible to see tangles in the living brain using a Positron Emission Tomography (PET) scan.

This study is seeking hospice patients, aged 50 and older, who are willing to help achieve this goal of improved Alzheimer’s diagnosis. However, volunteers do not need to have Alzheimer’s or dementia. Participation involves a brief screening visit (which can take place at home), a 18F-AV-1451 PET scan at Harborview Medical Center, and consent to an examination of their brain after they die. The findings in their brain autopsy would then be compared to their PET scan to determine if 18F-AV-1451 truly provides a valid measure of the presence or absence of neurofibrillary tangles.

UW Medicine will provide round-trip transportation for the participant to come in to Harborview for a PET scan. Participants will be reimbursed $100 for the initial screening visit and $250 for the scan. Brain autopsy results will be made available to the participant’s family.

 

Key UW researcher: Kimiko Domoto-Reilly

Study Coordinator: Daniel Peterson at djpeters@u.washington.edu


DIAN-TU

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer Disease Caused by a Genetic Mutation.

DIAN-TU is the first prevention trial for Autosomal Dominant Alzheimer’s Disease (ADAD) families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.

Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of the studies conducted by this unit will have implications for future studies and treatments in sporadic Alzheimer’s disease. Currently the DIAN-TU-001 treatment trial is the only ongoing, active clinical trial within the DIAN-TU. The Enrollment Criteria for this trial can be found on the trial brochure link below. As new trials become available, information will continue to be posted.

Key UW Researcher: Suman Jayadev, MD
Study Contact: The DIAN Expanded Registry at www.DIANexr.org or 1-844-DIAN-EXR (342-6397)

 
Eligibility

You may be eligible for DIAN-2 if you answer ‘Yes’ to all of the following:

  • Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer’s disease (less than 60 years) in multiple generations?
  • Are you cognitively normal, or do you have mild dementia? Both are eligible for this prevention trial.
  • Are you between the ages 18 to 80?
  • Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
  • Do you have a family member or friend that can accompany you to visits and provide information about your medical history?
For More Information

Sort by Trial Type

GOLD: Brain Games to Overcome Late Life Depression

The University of Washington Department of Psychiatry and Behavioral Sciences is conducting a research study to see whether new treatments are effective for depressed, older adults.

We are looking for people aged 60 and older who are struggling with mood, depression or low energy. Every day we learn more and more about what causes depression. We know that not everyone is depressed for the same reasons and that there is no “one-size-fits-all” treatment for low mood, concentration and energy. Can a video game that helps older brains work like younger brains be useful in treating depression? Answering this question will help us develop “brain games” that can treat certain types of depression. Participants must be able to participate in MRI scans.

 

Participant Eligibility

Age 60- 80
Experiencing symptoms of depression
Able to participate in MRI scans

 

Key UW researcher Patricia Areán

Contact Mary Ann Barnard (206) 616-2129

For More Information

HABIT® Healthy Action to Benefit Independence & Thinking

*Study In Progress - Currently Not Enrolling

HABIT® Healthy Action to Benefit Independence & Thinking - A 10-Day Brain and Body Wellness Program for people living with mild cognitive impairment and a support partner

The Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD) Study of HABIT

HABIT is a 10-day program offered to individuals with cognitive impairment. A support partner is required to complete the program with the participant. The program builds on existing strengths and recognizes that procedural memory, otherwise known as 'habit,' can be exercised to promote the highest level of function and independence.

In the CEPIPODD study, participants will be randomly assigned to engage daily in 4 of these 5 components of HABIT:

  • Individual memory compensation training
  • Group supportive therapy
  • Yoga
  • Brain fitness
  • Wellness education

These sessions are delivered by a caring, multidisciplinary HABIT team including psychologists, education specialists, cognitive interventionalists, and exercise specialists.

Key UW Researcher: Vaishali Phatak

Study Contact: Marigrace Becker at mbecker1@uw.edu | 206.744.2017


Brain Aging in Vietnam War Veterans (DOD-ADNI)

Official Title: Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)

Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat-related problems and may be associated with a greater risk of Alzheimer's disease. This study will examine the possible connections between TBI and PTSD, and the signs and symptoms of Alzheimer's in Vietnam War veterans as they age.

 

Key ADRC Researcher Elaine Peskind, MD

Study Contact Jacqueline Hayes | 415-221-4810 | Jacqueline.Hayes@va.gov


Imaging Dementia—Evidence for Amyloid Scanning (IDEAS)

The Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study will assess the clinical usefulness and impact on patient-oriented outcomes of a brain positron emission tomography (PET) scan that detects amyloid plaques, a core feature of Alzheimer’s disease, in patients with mild cognitive impairment (MCI) or dementia of uncertain cause.

In this study, scientists want to learn how images of the brain may be able to help your doctor diagnose and treat your condition, and if that knowledge and treatment may lead to better health outcomes.

 

You may be eligible to participate in the IDEAS Study if you:

Are a Medicare beneficiary, 65 years of age or older.

Have ongoing memory problems or confusion and your doctor has not found the cause of your symptoms.

Have a medical history and cognitive testing that supports the diagnosis of either dementia or mild cognitive impairment, but the cause is not clear.

Have possible Alzheimer's disease, but your signs and symptoms are unusual.

 

How do I get involved?

To be part of the study, you will need to:

1) Be evaluated by a doctor who is an IDEAS Study dementia specialist at UW Medicine who can determine if you can participate in this research study.

2) Visit an IDEAS Study PET facility for a brain amyloid PET scan upon physician referral. This could be at a hospital or an outpatient center.

3) After the amyloid PET scan, complete a follow-up visit with the dementia specialist to discuss the results.

 

Key UW researcher: Dr. Kimiko Domoto-Reilly

IDEAS Study Contact: Christina Caso cdcaso@uw.edu or 206-221-9038


Neuroimaging and Function Study

The purpose of this UW Department of Rehabilitation Medicine study is to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems.  The study involves two visits (one year apart) to the University of Washington Health Sciences Center.  At the first visit a magnetic resonance imaging (MRI) is taken of the brain.  Walking, balance and memory tests are completed.  At the second visit only walking, balance and memory tests are completed. Taxi transportation is provided if needed.  Participants receive $50 for the first visit and $30 for the second visit.

 

Key Researcher: Ellen McGough, PhD, UW Assistant Professor, Department of Rehabilitation Medicine

Study Coordinator: Monica Smersh

Study Contact Number: 206-598-6139 or 206-616-5550

For More Information

The 18F-AV-1451 Autopsy Study

Avid Radiopharmaceuticals is evaluating a new imaging tracer, 18F-AV-1451, to see if it can identify the build-up of tau protein associated with Alzheimer’s disease and other conditions that lead to dementia. Tau accumulation in the brain can gradually cause problems with thinking and remembering. Until now, these tau tangles could only be seen by using a microscope to look at the brain of a patient after they died. This study aims to determine if, using 18F-AV-1451, it may be possible to see tangles in the living brain using a Positron Emission Tomography (PET) scan.

This study is seeking hospice patients, aged 50 and older, who are willing to help achieve this goal of improved Alzheimer’s diagnosis. However, volunteers do not need to have Alzheimer’s or dementia. Participation involves a brief screening visit (which can take place at home), a 18F-AV-1451 PET scan at Harborview Medical Center, and consent to an examination of their brain after they die. The findings in their brain autopsy would then be compared to their PET scan to determine if 18F-AV-1451 truly provides a valid measure of the presence or absence of neurofibrillary tangles.

UW Medicine will provide round-trip transportation for the participant to come in to Harborview for a PET scan. Participants will be reimbursed $100 for the initial screening visit and $250 for the scan. Brain autopsy results will be made available to the participant’s family.

 

Key UW researcher: Kimiko Domoto-Reilly

Study Coordinator: Daniel Peterson at djpeters@u.washington.edu


A4 Study

Anti-amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) prevention clinical trial

The A4 Study is a landmark clinical trial that is testing a new drug that may help slow memory loss associated with Alzheimer’s disease. [Read about A4 in Spanish.]

 

You may be eligible to join the A4 study if you:

Are 65 to 85 years old

Have normal thinking and memory abilities

Have an A4 study partner – someone who has at least weekly contact with you who can answer questions once a year

Are willing and able to receive IV infusions of the investigational treatment or placebo for 36 months (36 monthly infusions); all A4 participants must be willing and able to participate in all required procedures for the duration of the A4 study.

Are willing to have your health monitored throughout the study using assessments such as:

Memory and thinking tests

ECGs (a look at your heart)

PET scan (a way to look for the plaques thought to be associated with AD)

MRI scans (a way to take a picture of your brain)

Blood and urine tests

 

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

DIAN-TU

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer Disease Caused by a Genetic Mutation.

DIAN-TU is the first prevention trial for Autosomal Dominant Alzheimer’s Disease (ADAD) families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.

Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of the studies conducted by this unit will have implications for future studies and treatments in sporadic Alzheimer’s disease. Currently the DIAN-TU-001 treatment trial is the only ongoing, active clinical trial within the DIAN-TU. The Enrollment Criteria for this trial can be found on the trial brochure link below. As new trials become available, information will continue to be posted.

Key UW Researcher: Suman Jayadev, MD
Study Contact: The DIAN Expanded Registry at www.DIANexr.org or 1-844-DIAN-EXR (342-6397)

 
Eligibility

You may be eligible for DIAN-2 if you answer ‘Yes’ to all of the following:

  • Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer’s disease (less than 60 years) in multiple generations?
  • Are you cognitively normal, or do you have mild dementia? Both are eligible for this prevention trial.
  • Are you between the ages 18 to 80?
  • Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
  • Do you have a family member or friend that can accompany you to visits and provide information about your medical history?
For More Information

Biogen Emerge

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

The EMERGE Study is a global study assessing the efficacy and safety of monthy doses of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease or prevent dementia. There is an important medical and scientific need to research therapies that could delay memory loss and the progression of disability in Alzheimer’s disease because there are currently no approved treatments that slow the course of the condition.

 

You may be eligible to participate in EMERGE if you

  • are 50-85 years old
  • are experiencing symptoms that may be related to early Alzheimer’s disease, such as problems with memory or thinking clearly.

 

Key UW researcher: Suman Jayadev, MD

Study Coordinator: Teah Hoopes, thoopes@uw.edu or 1-844-861-9373 (toll free)


CONNECT

A Multi-Center, Double-Blind, Placebo-Controlled Phase 11a Study to Evaluate an Investigational Medicine to Treat Mild Alzheimer's Disease. The CONNECT Study will test whether an experimental drug, AZD0530 (saracatinib) will slow the progression in mild-stage Alzheimer's disease.

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

SNIFF

The Study of Nasal Insulin to Fight Forgetfulness (SNIFF)

This Phase II/III clinical trial will examine whether a type of insulin, when administered intranasally (as a nasal spray), improves memory in adults with a mild cognitive impairment or Alzheimer’s disease. The study will also provide evidence about how intranasal insulin works in the body.

Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

All Clinical Trials

A4 Study

Anti-amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) prevention clinical trial

The A4 Study is a landmark clinical trial that is testing a new drug that may help slow memory loss associated with Alzheimer’s disease. [Read about A4 in Spanish.]

 

You may be eligible to join the A4 study if you:

Are 65 to 85 years old

Have normal thinking and memory abilities

Have an A4 study partner – someone who has at least weekly contact with you who can answer questions once a year

Are willing and able to receive IV infusions of the investigational treatment or placebo for 36 months (36 monthly infusions); all A4 participants must be willing and able to participate in all required procedures for the duration of the A4 study.

Are willing to have your health monitored throughout the study using assessments such as:

Memory and thinking tests

ECGs (a look at your heart)

PET scan (a way to look for the plaques thought to be associated with AD)

MRI scans (a way to take a picture of your brain)

Blood and urine tests

 

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

Biogen Emerge

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

The EMERGE Study is a global study assessing the efficacy and safety of monthy doses of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease or prevent dementia. There is an important medical and scientific need to research therapies that could delay memory loss and the progression of disability in Alzheimer’s disease because there are currently no approved treatments that slow the course of the condition.

 

You may be eligible to participate in EMERGE if you

  • are 50-85 years old
  • are experiencing symptoms that may be related to early Alzheimer’s disease, such as problems with memory or thinking clearly.

 

Key UW researcher: Suman Jayadev, MD

Study Coordinator: Teah Hoopes, thoopes@uw.edu or 1-844-861-9373 (toll free)

Brain Aging in Vietnam War Veterans (DOD-ADNI)

Official Title: Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)

Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat-related problems and may be associated with a greater risk of Alzheimer's disease. This study will examine the possible connections between TBI and PTSD, and the signs and symptoms of Alzheimer's in Vietnam War veterans as they age.

 

Key ADRC Researcher Elaine Peskind, MD

Study Contact Jacqueline Hayes | 415-221-4810 | Jacqueline.Hayes@va.gov

CONNECT

A Multi-Center, Double-Blind, Placebo-Controlled Phase 11a Study to Evaluate an Investigational Medicine to Treat Mild Alzheimer's Disease. The CONNECT Study will test whether an experimental drug, AZD0530 (saracatinib) will slow the progression in mild-stage Alzheimer's disease.

Key UW researcher: Elaine Peskind, MD

Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

DIAN-TU

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer Disease Caused by a Genetic Mutation.

DIAN-TU is the first prevention trial for Autosomal Dominant Alzheimer’s Disease (ADAD) families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.

Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of the studies conducted by this unit will have implications for future studies and treatments in sporadic Alzheimer’s disease. Currently the DIAN-TU-001 treatment trial is the only ongoing, active clinical trial within the DIAN-TU. The Enrollment Criteria for this trial can be found on the trial brochure link below. As new trials become available, information will continue to be posted.

Key UW Researcher: Suman Jayadev, MD
Study Contact: The DIAN Expanded Registry at www.DIANexr.org or 1-844-DIAN-EXR (342-6397)

 
Eligibility

You may be eligible for DIAN-2 if you answer ‘Yes’ to all of the following:

  • Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer’s disease (less than 60 years) in multiple generations?
  • Are you cognitively normal, or do you have mild dementia? Both are eligible for this prevention trial.
  • Are you between the ages 18 to 80?
  • Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
  • Do you have a family member or friend that can accompany you to visits and provide information about your medical history?
For More Information

GOLD: Brain Games to Overcome Late Life Depression

The University of Washington Department of Psychiatry and Behavioral Sciences is conducting a research study to see whether new treatments are effective for depressed, older adults.

We are looking for people aged 60 and older who are struggling with mood, depression or low energy. Every day we learn more and more about what causes depression. We know that not everyone is depressed for the same reasons and that there is no “one-size-fits-all” treatment for low mood, concentration and energy. Can a video game that helps older brains work like younger brains be useful in treating depression? Answering this question will help us develop “brain games” that can treat certain types of depression. Participants must be able to participate in MRI scans.

 

Participant Eligibility

Age 60- 80
Experiencing symptoms of depression
Able to participate in MRI scans

 

Key UW researcher Patricia Areán

Contact Mary Ann Barnard (206) 616-2129

For More Information

HABIT® Healthy Action to Benefit Independence & Thinking

*Study In Progress - Currently Not Enrolling

HABIT® Healthy Action to Benefit Independence & Thinking - A 10-Day Brain and Body Wellness Program for people living with mild cognitive impairment and a support partner

The Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD) Study of HABIT

HABIT is a 10-day program offered to individuals with cognitive impairment. A support partner is required to complete the program with the participant. The program builds on existing strengths and recognizes that procedural memory, otherwise known as 'habit,' can be exercised to promote the highest level of function and independence.

In the CEPIPODD study, participants will be randomly assigned to engage daily in 4 of these 5 components of HABIT:

  • Individual memory compensation training
  • Group supportive therapy
  • Yoga
  • Brain fitness
  • Wellness education

These sessions are delivered by a caring, multidisciplinary HABIT team including psychologists, education specialists, cognitive interventionalists, and exercise specialists.

Key UW Researcher: Vaishali Phatak

Study Contact: Marigrace Becker at mbecker1@uw.edu | 206.744.2017

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS)

The Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study will assess the clinical usefulness and impact on patient-oriented outcomes of a brain positron emission tomography (PET) scan that detects amyloid plaques, a core feature of Alzheimer’s disease, in patients with mild cognitive impairment (MCI) or dementia of uncertain cause.

In this study, scientists want to learn how images of the brain may be able to help your doctor diagnose and treat your condition, and if that knowledge and treatment may lead to better health outcomes.

 

You may be eligible to participate in the IDEAS Study if you:

Are a Medicare beneficiary, 65 years of age or older.

Have ongoing memory problems or confusion and your doctor has not found the cause of your symptoms.

Have a medical history and cognitive testing that supports the diagnosis of either dementia or mild cognitive impairment, but the cause is not clear.

Have possible Alzheimer's disease, but your signs and symptoms are unusual.

 

How do I get involved?

To be part of the study, you will need to:

1) Be evaluated by a doctor who is an IDEAS Study dementia specialist at UW Medicine who can determine if you can participate in this research study.

2) Visit an IDEAS Study PET facility for a brain amyloid PET scan upon physician referral. This could be at a hospital or an outpatient center.

3) After the amyloid PET scan, complete a follow-up visit with the dementia specialist to discuss the results.

 

Key UW researcher: Dr. Kimiko Domoto-Reilly

IDEAS Study Contact: Christina Caso cdcaso@uw.edu or 206-221-9038

Meal and Memory Study

APOE genotype and diet influences on Alzheimer's biomarkers

We are learning more and more about the risks for Alzheimer's disease every year, and that includes learning what foods are best at promoting brain health.  It might be more complicated than 'this food is good or bad.'  Dr. Angela Hanson, a geriatric physician at the University of Washington, is conducting a study that examines how a risk gene for Alzheimer's disease might affect people's memory and metabolic responses to different meals.  Her preliminary work showed that people who carry the gene APOE4 (E4) responded differently to different Alzheimer's treatments and diets, compared to people who did not carry this gene.  Dr. Hanson plans to study this further with the "Meal and Memory Study” in adults age 55 and older who do not have dementia. 

 

Eligibility: Participants may be men or women, ages 55 and older. People who have known dementia, or known diabetes, are not eligible.

 

Key researcher:  Angela Hanson, MD

Study Contact: Angela Hanson at 206-897-5393 or hansonaj@uw.edu

For More Information

Neuroimaging and Function Study

The purpose of this UW Department of Rehabilitation Medicine study is to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems.  The study involves two visits (one year apart) to the University of Washington Health Sciences Center.  At the first visit a magnetic resonance imaging (MRI) is taken of the brain.  Walking, balance and memory tests are completed.  At the second visit only walking, balance and memory tests are completed. Taxi transportation is provided if needed.  Participants receive $50 for the first visit and $30 for the second visit.

 

Key Researcher: Ellen McGough, PhD, UW Assistant Professor, Department of Rehabilitation Medicine

Study Coordinator: Monica Smersh

Study Contact Number: 206-598-6139 or 206-616-5550

For More Information

SNIFF

The Study of Nasal Insulin to Fight Forgetfulness (SNIFF)

This Phase II/III clinical trial will examine whether a type of insulin, when administered intranasally (as a nasal spray), improves memory in adults with a mild cognitive impairment or Alzheimer’s disease. The study will also provide evidence about how intranasal insulin works in the body.

Key UW researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta, rantaa@uw.edu or 206.764.2339

For More Information

The 18F-AV-1451 Autopsy Study

Avid Radiopharmaceuticals is evaluating a new imaging tracer, 18F-AV-1451, to see if it can identify the build-up of tau protein associated with Alzheimer’s disease and other conditions that lead to dementia. Tau accumulation in the brain can gradually cause problems with thinking and remembering. Until now, these tau tangles could only be seen by using a microscope to look at the brain of a patient after they died. This study aims to determine if, using 18F-AV-1451, it may be possible to see tangles in the living brain using a Positron Emission Tomography (PET) scan.

This study is seeking hospice patients, aged 50 and older, who are willing to help achieve this goal of improved Alzheimer’s diagnosis. However, volunteers do not need to have Alzheimer’s or dementia. Participation involves a brief screening visit (which can take place at home), a 18F-AV-1451 PET scan at Harborview Medical Center, and consent to an examination of their brain after they die. The findings in their brain autopsy would then be compared to their PET scan to determine if 18F-AV-1451 truly provides a valid measure of the presence or absence of neurofibrillary tangles.

UW Medicine will provide round-trip transportation for the participant to come in to Harborview for a PET scan. Participants will be reimbursed $100 for the initial screening visit and $250 for the scan. Brain autopsy results will be made available to the participant’s family.

 

Key UW researcher: Kimiko Domoto-Reilly

Study Coordinator: Daniel Peterson at djpeters@u.washington.edu